Cantargia – executive interview

Published on 15 March 2021

Cantargia is a clinical-stage biotechnology company based in Sweden, established in 2009 and listed on the Nasdaq Stockholm main market. It is developing two assets against IL1RAP, CAN04 and CAN10. The lead clinical trial is a Phase IIa CANFOUR study with CAN04 in non-small cell lung cancer and pancreatic cancer. Cantargia is also running a Phase I trial in the United States with CAN04 in combination with checkpoint inhibitors in various solid tumours. Another Phase Ib trial is being prepared and will expand the target patient population in pancreatic cancer.

In this video, Göran Forsberg, Cantargia’s chief executive officer, addresses the recent news flow for Novartis, which has announced results from one of its Phase III trials with a potential competitor drug. He then provides an overview of Cantargia’s latest R&D progress and expected rich news flow this year.

Share this with friends and colleagues